Abstract:Molecular imaging represents a powerful tool for the immediate diagnosis of early gastric cancers (EGCs). In this study, the human heavy-chain ferritin (HFn), which specifically recognizes tumor biomarker transferrin receptor-1 (TfR1), was labeled with fluorescent agents to enable real-time imaging by confocal laser endomicroscopy (CLE). : In vivo molecular imaging was performed in tumor-bearing mice from gastric cancer cell lines (BGC-823 and SGC-7901). Xenograft tumors were visualized in vivo first with a whole-body fluorescent imaging device and then by CLE using fluorescently labeled HFn-nanoprobe. Human EGC specimens were examined ex vivo by HFn-nanoprobe-based CLE. 1. Generation of the HFn-nanoprobe, and its specific conjunction with gastric cancer cell. We labeled the protein shell of HFn with a dye for ex vivo tumor-cell imaging, in vivo fluorescence molecular imaging, and ex vivo CLE imaging; and we bio-mimetically synthesized magneto-HFn nanoparticle (M-HFn) for tissue IHC staining. The protein shells of both dye-HFn and M-HFn nanoprobes presented a well-defined morphology and were monodisperse in size. Western blotting and FACS results showed the general expression of TfR1 in BGC-823 and SGC-7901 cells. After tumor cells incubated with FITC-HFn, FITC-HFn showed membranous and cytoplasmic staining patterns. 2. Macroscopic Fluorescence Detection of TfR1 in Mice. We used macroscopic whole-body fluorescence detection to examine tumor-targeting efficacy of HFn labeled with IRDye800CW-HFn in mice harboring BGC-823 and SGC-7901 cells. Both tumor models showed increased HFn-targeted imaging and specific fluorescence signals in the tumors 4 h after tail-vein injection of IRDye800CW-HFn and the signals were still detectable at 48 h after HFn administration. The results were verified by ex vivo bench-top fluorescence-microscopy imaging and M-HFn IHC staining of the tumor xenografts (Fig.1). 3. HFn Binding to Human EGC Tissues Ex Vivo. Twenty-two cases EGC specimens after endoscopic submucosal dissection were available. After the incubation with FITC-HFn on EGC specimens , all EGCs showed specific FITC-HFn signal (22/22), whereas noncancerous tissues exhibited no (21/22) or weak specific fluorescence (1/22) (P < 0.0001). There is negative correlation between degree of HFn fluorescence signal and degree of tumor differentiation. The results were verified by the IHC and bench-top fluorescence staining. Our results also showed FITC-HFn-CLE imaging provided high contrast between cancerous and noncancerous tissues (Fig.2). Our HFn-nanoprobe-based CLE method is a promising approach for detection of EGCs, and this TfR1-targeted molecular imaging increases the accuracy of EGC detection and enables the visualization of tumor margins and guiding endoscopic resection.Fig. 2FITC-HFn identifies EGC. In the white-light image, a tumor-lesion area (A) was confirmed through histological analysis; the area is shown as regions 1 and 2 (B). The FITC-HFn probe was topically applied onto the tumor specimen (C and D) for staining. Stereomicroscopy imaging revealed specific fluorescence was detected in the tumorous regions 1 and 2 after FITC-HFn staining (E and F). Under CLE, a specific signal was detected in cancerous lesions, and high-magnification imaging showed strong membranous and cytoplasmic staining (G and H). The results of the IHC and bench-top fluorescence staining of the targeted tissue were confirmed through H&E staining (I-K; red dashed line: diseased area).View Large Image Figure ViewerDownload Hi-res image Download (PPT)

Deciphering the Role of H-Ferritin Nanocages in Improving Tumor-Targeted Delivery of Indocyanine Green: Combined Analysis of Murine Tissue Homogenates with UHPLC-MS/MS and Fluorescence

Combined Ferritin Nanocarriers with ICG for Effective Phototherapy Against Breast Cancer

Ferritin nanocages for early theranostics of tumors via inflammation-enhanced active targeting

Ferritin in cancer therapy: A pleiotropic tumoraffin nanocage‐based transport

Multifunctional Ferritin Nanoparticles As Theranostics for Imaging-Guided Tumor Phototherapy.

Mechanism Study of Thermally Induced Anti-Tumor Drug Loading to Engineered Human Heavy-Chain Ferritin Nanocages Aided by Computational Analysis

Endoscopic Molecular Imaging of Early Gastric Cancer Using Fluorescently Labeled Human H-ferritin Nanoparticle.

Transformable nanotherapeutics enabled by ICG: towards enhanced tumor penetration under NIR light irradiation

Design, preparation and pharmacodynamics of ICG-Fe(III) based HCPT nanocrystals against cancer

H‐Chain Ferritin: A Natural Nuclei Targeting and Bioactive Delivery Nanovector

Sa1221 ENDOSCOPIC MOLECULAR IMAGING OF EARLY GASTRIC CANCER USING HUMAN HEAVY-CHAIN FERRITIN NANOPROBE UNDER CONFOCAL LASER ENDOMICROSCOPY

Re-engineering the inner surface of ferritin nanocage enables dual drug payloads for synergistic tumor therapy

Design, Preparation and Pharmacodynamics of ICG-Fe(Ⅲ) Based HCPT Nanocrystals Against Cancer.

In Vitro Immunoreactivity Evaluation of H-Ferritin-Based Nanodrugs

Targeting of cancer cells with ferrimagnetic ferritin cage nanoparticles

Lactoferrin Docking NIR-II Cyanine Dye As a Potentiated Phototheranostic for Synchronous Multimodal Bioimaging and Tumor Photo-Immunotherapy

Quantitative Evaluation Of Hepatobiliary Transporter Density With Microscopic Fluorescence Imaging Using Indocyanine Green

Ferritin nanocage with intrinsically disordered proteins and affibody: A platform for tumor targeting with extended pharmacokinetics

H-Ferritin-Nanocaged Doxorubicin Nanoparticles Specifically Target And Kill Tumors With A Single-Dose Injection

A supramolecular colloidal system based on folate-conjugated β-cyclodextrin polymer and indocyanine green for enhanced tumor-targeted cell imaging in 2D culture and 3D tumor spheroids

Human ferritin nanocarriers for drug-delivery: A molecular view of the disassembly process